NEW YORK (GenomeWeb) – Horizon Discovery announced today that it has partnered with Roche subsidiary Ventana Medical Systems to develop and commercialize cell line derivative material for use as immunohistochemistry (IHC) reference standards in cancer tissue diagnostics.
Under the terms of the deal, Ventana may commission Horizon on a project-by-project basis to develop specific cells line and associated derivative reference standard material. Horizon will be primarily responsible for commercializing the reference standards and will act as the primary distributor to end customers in the tissue diagnostics market. Ventana will have the option to co-distribute any of the reference standards.
Horizon said that it has the potential to receive annual development fees, subject to Ventana's opt-in rights. Additional terms of the arrangement were not disclosed.
"By securing this agreement, Horizon's reference standards will now be used increasingly in the IHC market, continuing the company’s successful strategy of embedding [off-the-shelf] products into established and emerging workflows, delivering reliable revenue streams at high margin," Horizon CEO Darrin Disley said in a statement.
The deal with Ventana marks the latest in a series of agreements Horizon has inked for its reference standards recently. In April, the company partnered with Agena Bioscience to incorporate Horizon's human genomic reference standards into MassArray oncology-based assays.
And last year, Horizon signed similar agreements for reference standards with Swift Biosciences, Bioké, and CareDx.